Replies to post #20828 on RespireRx Pharmaceuticals Inc (RSPI)

[jerrydylan]

I am not going to recount a conversation word for word but I surmised there was some positive data imbedded below 2100mgs. that was compromised by procedural issues, hence DSMB action. That seems pretty obvious? Yes.

[food4thought]

Couldn't the RD-2 study be easily duplicated at this point by an interested BP in a non formal setting to verify poc at lower doses. With this delay, it seems almost prudent that cor or at least an interested BP would be able to initiate a study similar to the somewhat botched RD-2 study in house at lower cohorts simply to verify its effect at the lower doses. That alone could verify the study data, removing procedural doubt, allowing cor to work more confidently towards getting a deal done. Or, is the data only prevelant if analgesia is preserved, hence requiring the RD-1 data nontheless? Is this possible or am I smoking something? Would regulation issues not allow such an effort. With all the connections to various labs and drifters looking for extra cash I would think it wouldn't be to difficult a task.